ClinicalTrials.Veeva

Menu

" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "

S

Sohag University

Status

Not yet enrolling

Conditions

Immune Thrombocytopenic Purpura

Treatments

Diagnostic Test: Genotyping of rs1883832C/T related single-nucleotide polymorphism

Study type

Interventional

Funder types

Other

Identifiers

NCT05585944
Soh-Med-22-10-21

Details and patient eligibility

About

Immune thrombocytopenia is an acquired autoimmune disease, in which platelets are opsonized by auto-antibodies and destroyed by phagocytic cells .Genetic polymorphisms in the immune mediators have been suggested to play a pivotal role in the pathogenesis of many autoimmune disorders . Several genetic polymorphisms of the immune system genes have been described in ITP such as interleukins, tumor necrosis factors (TNF) alpha and beta, and interferon-gamma., These polymorphisms were found to be associated with an increased risk of ITP progression or exacerbation .CD40 is a co-stimulatory 4348 kDa glycoprotein molecule composed of 277 amino acid residues which belongs to the tumor necrosis family. It is encoded by a gene which is located at chromosome 20q11-13, expressed mainly on antigen presenting cells (APCs), some non-immune cells and tumors.Antinuclear antibodies (ANA) is a collective term for a large and heterogeneous group of circulating autoantibody. Reflecting their clinical importance, ANA are diagnostic, prognostic or classification criteria for many autoimmune diseases.

Enrollment

80 estimated patients

Sex

All

Ages

1 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • sign an informed written consent from the patients or their parents
  • patient with newly diagnosed ITP
  • patient age > 1 year and < 65 years and both sexes are included.

Exclusion criteria

  • Refusal to sign an informed written consent
  • patient with persistent ITP, patient with secondary immune thrombocytopenia
  • patient age < 1 year or > 65 years.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

80 participants in 2 patient groups

control
Active Comparator group
Description:
healthy participants
Treatment:
Diagnostic Test: Genotyping of rs1883832C/T related single-nucleotide polymorphism
cases
Active Comparator group
Description:
cases of immune thrombocytopenic purpura
Treatment:
Diagnostic Test: Genotyping of rs1883832C/T related single-nucleotide polymorphism

Trial contacts and locations

1

Loading...

Central trial contact

nagwa M Aboelmahasen, assisstant lecturer; Elham O Hamed, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems